US · ALVO · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Alvotech (ALVO) intrinsic value and stock valuation
$4.12as of 2026-11-21 · Mkt cap 1.27B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Alvotech DCF and intrinsic value
InvestorsCraft values ALVO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ALVO’s statements →
Alvotech Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- UFP Technologies, Inc. (UFPT) $290.85
- Biohaven Ltd. (BHVN) $12.39
- Progyny, Inc. (PGNY) $35.71
- Harrow Health, Inc. (HROW) $30.41
- Phibro Animal Health Corporation (PAHC) $33.29
- Collegium Pharmaceutical, Inc. (COLL) $24.72
- Amphastar Pharmaceuticals, Inc. (AMPH) $28.25
- Evotec SE (EVO) $1.32
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $586.3M | $489.7M | $91.4M | $83M | $36.8M |
| Operating income | $78.2M | $69.6M | -$-354.86M | -$-346.44M | -$-235.46M |
| Net income | $27.9M | -$-231.86M | -$-551.73M | -$-513.58M | -$-101.5M |
| EPSd | $100K | -$-865.41K | -$-2.43M | -$-2.6M | -$-3.25M |
| Operating cash flow | -$-50.2M | -$-236.84M | -$-312.19M | -$-312.39M | -$-228.17M |
| Capital expenditure | -$-64.47M | -$-57M | -$-46.47M | -$-49M | -$-40.63M |
| Free cash flow | -$-114.67M | -$-293.84M | -$-358.66M | -$-361.39M | -$-268.8M |
| Total assets | $1.49B | $1.22B | $950.1M | $828.4M | $598M |
| Total debt | $1.45B | $1.19B | $1.08B | $805.1M | $523.1M |
| Net debt | $1.28B | $1.14B | $1.06B | $738.7M | $505.5M |
| Total equity | -$-284.49M | -$-412.77M | -$-932.49M | -$-564.42M | -$-135.61M |
| Cash and short-term investments | $172.4M | $51.4M | $11.2M | $66.4M | $17.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $586.3M | $489.7M | $91.4M | $83M | $36.8M |
| Cost of revenue | $235.6M | $185.3M | $160.9M | $64.1M | $0.00 |
| Gross profit | $350.8M | $304.4M | -$-69.42M | $18.9M | $36.8M |
| Research and development expenses | $184.2M | $171.3M | $210.8M | $180.6M | $191M |
| Selling, general and administrative expenses | $91M | $61.5M | $73M | $186.7M | $84.1M |
| Other expenses | -$-2.58M | $1.96M | $1.57M | -$-1.99M | -$-2.91M |
| Operating expenses | $272.6M | $234.7M | $285.4M | $365.4M | $272.2M |
| Cost and expenses | $508.1M | $420M | $446.3M | $429.5M | $272.2M |
| Interest income | $198.5M | $4.62M | $4.82M | $910K | $20K |
| Interest expense | $149.2M | $157.6M | $134.8M | $91.4M | $113M |
| Depreciation and amortization | $37.9M | $31.3M | $24.2M | $20.4M | $18.2M |
| Ebitda | $323.4M | -$-32.27M | -$-493.67M | -$-439.8M | -$-18.03M |
| Operating income | $78.2M | $69.6M | -$-354.86M | -$-346.44M | -$-235.46M |
| Total other income/expenses, net | $58.1M | -$-287.21M | -$-296.19M | -$-205.21M | $86.3M |
| Income before tax | $136.4M | -$-217.56M | -$-651.05M | -$-551.65M | -$-149.2M |
| Income tax expense | $108.4M | $14.3M | -$-99.32M | -$-38.07M | -$-47.69M |
| Net income | $27.9M | -$-231.86M | -$-551.73M | -$-513.58M | -$-101.5M |
| Weighted average shares outstanding | $279.2M | $267.9M | $227.3M | $197.7M | $31.3M |
| Weighted average diluted shares outstanding | $279.2M | $267.9M | $227.3M | $197.7M | $31.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $172.4M | $51.4M | $11.2M | $66.4M | $17.6M |
| Net receivables | $153.8M | $251.7M | $87.2M | $71.4M | $53.9M |
| Inventory | $220.1M | $127.9M | $74.4M | $71.5M | $39.1M |
| Total current assets | $574M | $455M | $194.8M | $230.7M | $119.8M |
| Property, plant and equipment, net | $356.4M | $409.7M | $356.6M | $268.1M | $205.3M |
| Goodwill and intangible assets | $94.7M | $32M | $31.1M | $37.3M | $33.9M |
| Long-term investments | $122.9M | $22.7M | $18.5M | $48.6M | $55.3M |
| Total non-current assets | $913.1M | $766.4M | $755.3M | $597.7M | $478.2M |
| Total assets | $1.49B | $1.22B | $950.1M | $828.4M | $598M |
| Accounts payable | $126.1M | $67.1M | $80.6M | $49.2M | $28.6M |
| Short-term debt | $49M | $42.2M | $47.7M | $25.1M | $10.1M |
| Deferred revenue | $30.4M | $16M | $59.2M | $36.9M | $29.7M |
| Total current liabilities | $304.1M | $193.4M | $261M | $167.3M | $111.8M |
| Long-term debt | $1.4B | $1.15B | $1.03B | $780M | $513M |
| Deferred revenue, non-current | $5.5M | $80.7M | $73.3M | $57M | $44.8M |
| Total non-current liabilities | $1.47B | $1.44B | $1.62B | $1.23B | $621.8M |
| Capital lease obligations | $150.1M | $121.7M | $115.3M | $40.5M | $122.1M |
| Total liabilities | $1.77B | $1.63B | $1.88B | $1.39B | $733.6M |
| Common stock | $2.93M | $2.83M | $2.28M | $2.13M | $140K |
| Retained earnings | -$-2.41B | -$-2.44B | -$-2.21B | -$-1.65B | -$-1.14B |
| Accumulated other comprehensive income (loss) | $16.7M | $15.1M | $41.4M | $29.1M | $4.67M |
| Total equity | -$-284.49M | -$-412.77M | -$-932.49M | -$-564.42M | -$-135.61M |
| Total investments | $122.9M | $22.7M | $18.5M | $48.6M | $55.3M |
| Total debt | $1.45B | $1.19B | $1.08B | $805.1M | $523.1M |
| Net debt | $1.28B | $1.14B | $1.06B | $738.7M | $505.5M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $27.9M | -$-231.86M | -$-551.73M | -$-513.58M | -$-101.5M |
| Depreciation and amortization | $37.9M | $31.3M | $24.2M | $20.4M | $18.2M |
| Stock-based compensation | $17.4M | $7.63M | $18M | $10.3M | $0.00 |
| Change in working capital | -$-117.64M | -$-288.64M | $26.3M | -$-47.89M | -$-6.81M |
| Accounts receivable | -$-6.33M | -$-164.24M | -$-24.83M | -$-13.23M | -$-13.53M |
| Inventory | -$-90.13M | -$-49.97M | -$-11.3M | -$-32.41M | -$-29.41M |
| Accounts payable | -$-21.18M | $0.00 | $0.00 | $0.00 | $14.3M |
| Net cash provided by operating activities | -$-50.2M | -$-236.84M | -$-312.19M | -$-312.39M | -$-228.17M |
| Investments in property, plant and equipment | -$-64.47M | -$-53.66M | -$-33.23M | -$-37.88M | -$-20.46M |
| Acquisitions, net | -$-14.04M | $12M | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-104.22M | -$-18.87M | -$-46.34M | -$-63.54M | -$-40.63M |
| Common stock issued | $78.7M | $150.5M | $136.9M | $9.83M | $185.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $270.8M | $297.3M | $301.3M | $424.9M | $254.8M |
| Net change in cash | $120.9M | $40.3M | -$-55.27M | $48.9M | -$-14.13M |
| Cash at end of period | $172.4M | $51.4M | $11.2M | $66.4M | $17.6M |
| Operating cash flow | -$-50.2M | -$-236.84M | -$-312.19M | -$-312.39M | -$-228.17M |
| Capital expenditure | -$-64.47M | -$-57M | -$-46.47M | -$-49M | -$-40.63M |
| Free cash flow | -$-114.67M | -$-293.84M | -$-358.66M | -$-361.39M | -$-268.8M |
Line items
Line items
Line items
About Alvotech
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
- CEO
- Lisa Graver
- Employees
- 1.46K
- Beta
- 0.19
Explore
Frequently asked questions
What is the intrinsic value of Alvotech (ALVO)?
Alvotech (ALVO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ALVO undervalued?
ALVO trades at a price of $4.12 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.